Harrow (HROW) Cash from Financing Activities (2011 - 2026)
Harrow (HROW) posted quarterly Cash from Financing Activities of $48.9 million for Q1 2026, up 212560.87% year-over-year from N/an in Q1 2025, and up 1069.71% quarter-over-quarter from -$5.0 million in Q4 2025.
Harrow (HROW) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Harrow's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $48.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 212560.87% year-over-year to $48.9 million; the TTM figure through Mar 2026 stood at $36.2 million (up 23.18% YoY), while the FY2025 annual figure was -$12.7 million, down 144.6% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $48.9 million, up from -$5.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $64.2 million in Q3 2023, with the low at -$12.7 million in Q2 2025.
- The 5-year median for Cash from Financing Activities is $48000.0 (2024), against an average of $15.3 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities surged 2751500.0% in 2022, then plunged 17452.05% in 2025.
- Harrow's Cash from Financing Activities stood at $55.0 million in 2022, then tumbled by 100.03% to -$18000.0 in 2023, then surged by 166683.33% to $30.0 million in 2024, then sank by 116.82% to -$5.0 million in 2025, then surged by 1069.71% to $48.9 million in 2026.
- Business Quant data shows HROW's Cash from Financing Activities at $48.9 million in Q1 2026, -$5.0 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Harrow | 1.53 Bn | 1.45 Bn | 50.36 Mn | -466,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -466,000.00 |
| Jun 30, 2026 | -466,000.00 |
| Mar 31, 2026 | 48.91 Mn |
| Mar 31, 2026 | 48.91 Mn |
| Dec 31, 2025 | -5.04 Mn |
| Dec 31, 2025 | -5.04 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | -12.67 Mn |
| Jun 30, 2025 | -12.67 Mn |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 29.99 Mn |
| Dec 31, 2024 | 29.99 Mn |
| Sep 30, 2024 | -721,000.00 |
| Sep 30, 2024 | -721,000.00 |
| Jun 30, 2024 | 73,000.00 |
| Jun 30, 2024 | 73,000.00 |
| Mar 31, 2024 | -809,000.00 |
| Mar 31, 2024 | -809,000.00 |